DE69326016T2 - Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen - Google Patents

Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen

Info

Publication number
DE69326016T2
DE69326016T2 DE69326016T DE69326016T DE69326016T2 DE 69326016 T2 DE69326016 T2 DE 69326016T2 DE 69326016 T DE69326016 T DE 69326016T DE 69326016 T DE69326016 T DE 69326016T DE 69326016 T2 DE69326016 T2 DE 69326016T2
Authority
DE
Germany
Prior art keywords
fibronectin
collagen
binding proteins
peptide inhibitors
related collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69326016T
Other languages
English (en)
Other versions
DE69326016D1 (de
Inventor
David Roberts
Henry Krutzch
John Sipes
Neng-Hua Guo
Eric Negre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69326016D1 publication Critical patent/DE69326016D1/de
Publication of DE69326016T2 publication Critical patent/DE69326016T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69326016T 1992-11-10 1993-11-09 Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen Expired - Fee Related DE69326016T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/973,235 US5491130A (en) 1992-11-10 1992-11-10 Peptide inhibitors of fibronectin and related collagen-binding proteins
PCT/US1993/011104 WO1994011395A1 (en) 1992-11-10 1993-11-09 Peptide inhibitors of fibronectin and related collagen-binding proteins

Publications (2)

Publication Number Publication Date
DE69326016D1 DE69326016D1 (de) 1999-09-16
DE69326016T2 true DE69326016T2 (de) 2000-04-13

Family

ID=25520653

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69326016T Expired - Fee Related DE69326016T2 (de) 1992-11-10 1993-11-09 Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen

Country Status (8)

Country Link
US (2) US5491130A (de)
EP (1) EP0669937B1 (de)
JP (2) JP3789931B2 (de)
AT (1) ATE183196T1 (de)
AU (1) AU683234B2 (de)
CA (1) CA2148383A1 (de)
DE (1) DE69326016T2 (de)
WO (1) WO1994011395A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ263057A (en) * 1993-03-12 2000-12-22 Xoma Corp Use of bactericidal permeability increasing proteins or derivative for treating chronic inflammatory diseases, neutralising heparin, inhibiting angiogenesis, tumour and epithelial cell proliferation
JP3192067B2 (ja) * 1995-10-09 2001-07-23 科学技術振興事業団 ペプチドとコラーゲン収縮阻害剤
ATE309271T1 (de) 1996-05-16 2005-11-15 Texas A & M Univ Sys Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20020169108A1 (en) * 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US6716963B1 (en) 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
GB9903408D0 (en) * 1999-02-15 1999-04-07 Oxford Biomedica Ltd Peptides
CA2365949A1 (en) * 1999-04-16 2000-10-26 Children's Medical Center Corporation Adhesion modulatory peptides and methods for use
CN1301723A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——纤维结合蛋白类型ii10和编码这种多肽的多核苷酸
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
BR0113737A (pt) * 2000-09-07 2004-02-25 Schering Ag Receptor do domìnio da edbfibronectina (11)
EP1224943A1 (de) * 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin als Tumor Marker, detektiert durch auf Phagen exprimierte Antikörper
WO2002074324A1 (en) * 2001-03-15 2002-09-26 The Texas A & M University System Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2007502623A (ja) * 2003-05-09 2007-02-15 リサーチ ディベロップメント ファウンデーション 膜タンパク質におけるフリンプロテアーゼ開裂部位の挿入およびその使用法
US20060024725A1 (en) * 2004-07-30 2006-02-02 Robert Hussa Oncofetal fibronectin as a marker for pregnancy-related indications
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
BRPI0911945A2 (pt) 2008-05-13 2015-10-13 Clarassance Inc cc10 humana recombinante e suas composições para uso no tratamento de rinite nasal
CA2732102C (en) * 2008-08-07 2018-01-02 Jeffrey S. Isenberg Radioprotectants targeting thrombospondin-1 and cd47
CN102834115B (zh) 2009-10-15 2015-01-14 克拉莱森公司 用于治疗流感的重组人cc10蛋白
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
WO2013155109A1 (en) 2012-04-09 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for generation of pluripotent and multipotent cells
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP3125907A4 (de) 2014-04-01 2017-11-29 Cornell University Verwendung von doppelsträngiger dna in exosomen: neuartiger biomarker zur krebsdetektion
FR3024364B1 (fr) 2014-07-31 2016-09-02 Neuronax Oligopeptides particuliers comme medicaments anti-angiogeniques
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
WO2016172710A2 (en) 2015-04-24 2016-10-27 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
EP3870598A1 (de) 2018-10-23 2021-09-01 Dragonfly Therapeutics, Inc. Heterodimere fc-kondensierte proteine
IL297495A (en) 2020-04-22 2022-12-01 Dragonfly Therapeutics Inc Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1001013A4 (fr) * 1987-10-22 1989-06-13 Icp Internat Inst Of Cellular Derives de synergimycines de types a et b, procede pour leur preparation et utilisation de ceux-ci.
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin

Also Published As

Publication number Publication date
ATE183196T1 (de) 1999-08-15
JP3789931B2 (ja) 2006-06-28
CA2148383A1 (en) 1994-05-26
US5849701A (en) 1998-12-15
AU683234B2 (en) 1997-11-06
US5491130A (en) 1996-02-13
EP0669937B1 (de) 1999-08-11
WO1994011395A1 (en) 1994-05-26
JP2006028195A (ja) 2006-02-02
EP0669937A1 (de) 1995-09-06
AU5669594A (en) 1994-06-08
JPH08510715A (ja) 1996-11-12
DE69326016D1 (de) 1999-09-16

Similar Documents

Publication Publication Date Title
DE69326016D1 (de) Peptidinhibitoren von fibronectin und verwandten kollagen-bindenden proteinen
ATE196428T1 (de) Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
DE69812630D1 (de) Integrinbindendes peptid und dessen verwendung
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
ATE411388T1 (de) Zell-durchlässige peptidinhibitoren des jnk- signaltransduktionsweges
ATE380875T1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
ATE217754T1 (de) Verwendung von aerogelen in der landwirtschaft
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
HUP0105284A2 (hu) A haemostasisban és az immunfunkciókban használható inhibitorok
DE68917837D1 (de) Peptid-Verbindungen.
DE69919684D1 (de) Verwendung von isolierten domänen des type-iv-kollagens zur änderung der zell- und gewebewechselwirkung
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
ATE226591T1 (de) Oligopeptide hergeleitet von fragmenten des c- reaktiven proteins
ATE191223T1 (de) Verwendung von zelladhäsions-peptiden zur modifikation des haftungsvermögens eukaryontischer zellen untereinander
NO933423D0 (no) Modifisert blodplate-faktor-4
Daramola et al. Detection of fibronectin expression by human endothelial cells using a enzyme-linked immunosorbent assay (ELISA): enzymatic degradation by activated plasminogen
ES2109487T3 (es) Analogos de tetrapeptidos parcialmente modificados y retroinvertidos de fragmentos de proteina c-reactiva.
MY106261A (en) Anti-inflammatory 1-heteroaryl oxindole-3-carboxamides.
ATE160698T1 (de) Angiogenin und/oder alpha1-microglobulin und/oder komplementfaktor d zur begrenzung der sekretion von proteinen
NO910981L (no) Peptidforbindelser.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee